PRTA Profile — Prothena Corp Plc
Prothena is a biotechnology company engaged in the protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. Co. is developing a pipeline of therapeutic candidates for a number of indications and targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be utilized. Co.'s wholly-owned programs include birtamimab for the treatment of AL amyloidosis, a portfolio of programs for the treatment of Alzheimer's disease including PRX012 that targets Amyloid beta and a dual Amyloid beta-Tau vaccine.
|
|
Free PRTA Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.56 out of 4) 63rd percentile
(ranked higher than approx. 63% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |